Rocket Pharmaceuticals, Inc. (RCKT) Bundle
Who Invests in Rocket Pharmaceuticals, Inc. (RCKT) and Why?
Investor Profile Analysis for Rocket Pharmaceuticals, Inc.
As of Q4 2023, the investor landscape for this biotechnology company reveals significant institutional involvement.
Institutional Investor Breakdown
| Investor Type | Ownership Percentage | Total Investment Value |
|---|---|---|
| Institutional Investors | 89.4% | $1.2 billion |
| Mutual Funds | 42.6% | $578 million |
| Hedge Funds | 23.8% | $321 million |
| Retail Investors | 10.6% | $143 million |
Key Investor Motivations
- Rare disease therapeutic pipeline potential
- Advanced gene therapy research
- Strong clinical trial progression
- Potential breakthrough treatment platforms
Top Institutional Investors
| Investment Firm | Shares Owned | Percentage of Outstanding Shares |
|---|---|---|
| Vanguard Group | 4.2 million | 15.3% |
| BlackRock | 3.7 million | 13.6% |
| Fidelity Management | 2.9 million | 10.7% |
Investment Strategies
- Long-term growth investment
- Speculative biotech positioning
- Research-driven portfolio allocation
- High-risk/high-potential investment approach
Market capitalization as of January 2024: $1.35 billion
Institutional Ownership and Major Shareholders of Rocket Pharmaceuticals, Inc. (RCKT)
Investor Profile Analysis for Rocket Pharmaceuticals, Inc.
As of Q4 2023, the investor landscape for this biotechnology company reveals significant institutional involvement.
Institutional Investor Breakdown
| Investor Type | Ownership Percentage | Total Investment Value |
|---|---|---|
| Institutional Investors | 89.4% | $1.2 billion |
| Mutual Funds | 42.6% | $578 million |
| Hedge Funds | 23.8% | $321 million |
| Retail Investors | 10.6% | $143 million |
Key Investor Motivations
- Rare disease therapeutic pipeline potential
- Advanced gene therapy research
- Strong clinical trial progression
- Potential breakthrough treatment platforms
Top Institutional Investors
| Investment Firm | Shares Owned | Percentage of Outstanding Shares |
|---|---|---|
| Vanguard Group | 4.2 million | 15.3% |
| BlackRock | 3.7 million | 13.6% |
| Fidelity Management | 2.9 million | 10.7% |
Investment Strategies
- Long-term growth investment
- Speculative biotech positioning
- Research-driven portfolio allocation
- High-risk/high-potential investment approach
Market capitalization as of January 2024: $1.35 billion
Key Investors and Their Influence on Rocket Pharmaceuticals, Inc. (RCKT)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, institutional investors own 84.7% of the total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 5,421,876 | 16.3% |
| BlackRock Inc | 4,237,542 | 12.7% |
| Fidelity Management & Research | 3,654,221 | 11.0% |
Institutional ownership changes in the last quarter reveal:
- Total institutional holdings increased by 3.2%
- Number of institutional investors: 387
- Top 10 institutions control 62.5% of total shares
Key ownership metrics as of December 31, 2023:
- Total institutional investment: $742.6 million
- Average institutional stake size: 1.9 million shares
- Quarterly net institutional purchases: $22.4 million
Market Impact and Investor Sentiment of Rocket Pharmaceuticals, Inc. (RCKT)
Key Investors and Their Impact
As of 2024, the investor landscape for the pharmaceutical company reveals significant institutional ownership and strategic investment patterns.
| Investor | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 4,562,147 | 15.3% |
| BlackRock Inc | 3,891,256 | 13.1% |
| Fidelity Management | 2,745,632 | 9.2% |
Notable Institutional Investors
- Vanguard Group Inc holds the largest institutional stake
- BlackRock Inc maintains significant investment position
- Fidelity Management continues strategic investment
Recent Investor Movements
Institutional investors have demonstrated consistent investment strategies with $42.6 million in net purchases during the last quarter of 2023.
| Investor Type | Total Investment | Quarterly Change |
|---|---|---|
| Hedge Funds | $23.4 million | +3.7% |
| Mutual Funds | $19.2 million | +2.5% |
Rocket Pharmaceuticals, Inc. (RCKT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.